Search CommunityWalk:


Gliknik Inc.

801 W. Baltimore Street, Suite 501A
Baltimore, MD, USA

Category: Biotechnology/Biopharmaceutical

Used in the following map:

Maryland Biotech Industry Map

Gliknik Inc. is a biotech company focused on discovery, development and marketing of novel therapies for treating for patients with cancer and autoimmune or inflammatory diseases.

Gliknik has expertise in immune modulation. Its research platforms are: Immunomodulator platform - includes peptide drugs that generate immune responses against targeted cancer epitopes with the goal of turning a cancer patient's immune system against his or her tumor; Stradomer(TM) platform - includes recombinant drugs for a wide range of inflammatory and autoimmune diseases; Stradomer(TM) coated device platform - includes a drug coating to prevent the body's normal reaction to implanted devices; and Stradobody(TM) platform - includes biologics similar to monoclonal antibodies with increased tumor cell killing.

Gliknik's product pipeline includes: GL-2045, a recombinant version of intravenous immunoglobulin (IVIG) indicated for the treatment of autoimmune diseases; GN-4001, a nano-engineered stradomer indicated for the treatment of local inflammatory diseases; Stradobody(TM), represents antibody mimetics indicated for the treatment of cancer; GL-0810, a vaccine indicated for the treatment of head and neck squamous cell carcinoma(HNSCC); and GL-0817, a vaccine indicated for the treatment of head and neck squamous cell carcinoma (HNSCC) and myeloma.

Gliknik has agreements with The University of Maryland and Mayo Clinic. Its investors are LifeTech Development Partners and the MHCPDC investment fund.